<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343078">
  <stage>Registered</stage>
  <submitdate>20/06/2011</submitdate>
  <approvaldate>21/06/2011</approvaldate>
  <actrnumber>ACTRN12611000628943</actrnumber>
  <trial_identification>
    <studytitle>Is bias gas flow in ventilated preterm babies related to lung injury and risk of bronchopulmonary dysplasia?</studytitle>
    <scientifictitle>Ventilator bias gas flows in extremely preterm or extremely low birth weight babies: does a low bias gas flow compared with standard settings decrease concentrations of IL-8 in tracheal secretions and blood and the number of ventilated days?</scientifictitle>
    <utrn>U1111-1122-3024</utrn>
    <trialacronym>FLoRa: Flows at Lower Rates</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>ventilator-induced lung injury</healthcondition>
    <healthcondition>Bronchopulmonary dysplasia</healthcondition>
    <healthcondition>Extreme preterm birth</healthcondition>
    <healthcondition>Extremely low birth weight</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Complications of newborn</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 1:Conventional ventilation via ETT at a bias gas flow of 4 L/min
Arm 2: Conventional ventilation via ETT at a bias gas flow of 10 L/min
Duration; each time ventilation is indicated up to 36 weeks corrected gestational age</interventions>
    <comparator>Standard treatment of ventilation at a bias gas flow of 10 L/min</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Level of IL-8 in tracheal aspirate</outcome>
      <timepoint>Assessed at 24 hours after onset of ventilation</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of ventilated days</outcome>
      <timepoint>discharge from neonatal intensive care unit or death</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Levels of inflammatory markers IL-8, IL1-beta, IL-6 and TNF-alpha and levels of the oxidative stress markers myeloperoxidase activity, glutathione sulfonamide and chlorotyrosine in blood and tracheal aspirate</outcome>
      <timepoint>Assessed at 24, 72 and 120 hours after onset of ventilation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Bronchopulmonary dysplasia</outcome>
      <timepoint>36 weeks corrected postmenstrual age</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>mRNA Levels of early response genes CYR61, CTGF and EGR1 in blood samples, measured by molecular analysis</outcome>
      <timepoint>Assessed at 24, 72 and 120 hours after onset of ventilation</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Composite outcome of death or neonatal morbidity, including pulmonary interstitial emphysema, pulmonary haemorrhage, intraventricular haemorrhage (grade III and IV), periventricular leukomalacia, retinopathy of prematurity, necrotising enterocolitis or persistent ductus arteriosus.</outcome>
      <timepoint>36 weeks corrected postmenstrual age or death</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Occurrence of asthma or wheezing assessed by history and prescription of bronchodilators or inhaled corticosteroids</outcome>
      <timepoint>2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Preterm baby born before 28 weeks of gestation or birth weight &lt; 1,000 g and the need for mechanical ventilation in the first week of life</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Days</inclusiveminagetype>
    <inclusivemaxage>7</inclusivemaxage>
    <inclusivemaxagetype>Days</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Congenital cardio-respiratory anomalies and known chromosomal or genetic abnormalities</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Sealed opaque envelopes</concealment>
    <sequence>Randomisation from random number table stratified by centre</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/09/2011</anticipatedstartdate>
    <actualstartdate>27/07/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>180</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Christchurch</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Auckland</primarysponsorname>
    <primarysponsoraddress>Liggins Institute
University of Auckland
Private Bag 92019
Auckland 1142</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Anonymous philanthropic donation</fundingname>
      <fundingaddress>C/- Liggins Institute
University of Auckland
Private Bag 92019
Auckland 1142</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Cure Kids</fundingname>
      <fundingaddress>PO Box 90-907
Victoria Street West
Auckland, 1142</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>A+ Charitable trust fund</fundingname>
      <fundingaddress>ADHB
Private bag 92024
Auckland 1142</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Auckland City Hospital</sponsorname>
      <sponsoraddress>Newborn Services
National Women's Health
Auckland City Hospital
Support Building, level 9
PO Box 92024 
Auckland 1023</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>University of Otago</othercollaboratorname>
      <othercollaboratoraddress>Department of Paediatrics
Christchurch Clinical School, University of Otago
P.O. Box 4345, Level 5, 2 Riccarton Avenue, Christchurch 8140</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Hospital</othercollaboratortype>
      <othercollaboratorname>Royal Women's Hospital</othercollaboratorname>
      <othercollaboratoraddress>Royal Women's Hospital
Flemington Road
Parkville
Melbourne
Victoria 3050</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Mechanical ventilation of preterm babies has increased their survival over the last decades; however, ventilation also results in injury to the delicate immature lung. Several aspects of ventilation have been identified as contributing to this injury, including the pressure generated by the ventilator and the volume of gas delivered, which have led to advances in ventilatory strategies. To generate the pressure and tidal volume necessary to ventilate a patient, a ventilator applies a continuous bias gas flow running through the ventilator circuit. During ventilation of the preterm baby, this bias gas flow is normally set at 8-10 L/min, independent of babies weights and without evidence for this to be the correct setting. However, high compared to low ventilator bias gas flows have been proven to be more injurious for the immature lamb lung. This study will compare preterm babies ventilated at either the standard gas flow of 10 L/min, or a low gas flow of 4 L/min. Outcomes will be measurement of levels of inflammatory markers and duration and intensity of respiratory support</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Multi-region ethics committee</ethicname>
      <ethicaddress />
      <ethicapprovaldate>29/08/2011</ethicapprovaldate>
      <hrec>MEC11/08/068</hrec>
      <ethicsubmitdate>1/07/2011</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Frank Bloomfield</name>
      <address>Liggins Institute
University of Auckland
Private Bag 92019
Auckland 1142</address>
      <phone>+64 9 9236107</phone>
      <fax>+64 9 3737497</fax>
      <email>f.bloomfield@auckland.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Katinka Bach</name>
      <address>Newborn Services, Auckland City Hospital
Support Building, level 9
PO Box 92024 
Auckland 1023</address>
      <phone>+64 21 064 3439</phone>
      <fax>+64 9 3754373</fax>
      <email>kittyb@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Katinka Bach</name>
      <address>Newborn Services, Auckland City Hospital
Support Building, level 9
PO Box 92024 
Auckland 1023</address>
      <phone>+64 21 064 3439</phone>
      <fax>+64 9 3754373</fax>
      <email>kittyb@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Katinka Bach</name>
      <address>Newborn Services
Auckland City Hospital
Support Building level 9
Private bag 92024
Auckland 1023</address>
      <phone>+64 9 307 4949, ext 23526</phone>
      <fax />
      <email>kittyb@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>